{"id":"carmustin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Renal toxicity","drugRate":"","severity":"common","organSystem":""},{"effect":"Pneumonitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Pulmonary toxicity","drugRate":"","severity":"common","organSystem":""},{"effect":"Myelosuppression","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Alopecia","drugRate":"","severity":"common","organSystem":""},{"effect":"Hyperpigmentation","drugRate":"","severity":"common","organSystem":""},{"effect":"Erythema","drugRate":"","severity":"common","organSystem":""},{"effect":"Headaches","drugRate":"","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"","severity":"common","organSystem":""},{"effect":"Chest pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased transaminase","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased alkaline phosphatase","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased bilirubin","drugRate":"","severity":"common","organSystem":""},{"effect":"Burning sensation","drugRate":"","severity":"common","organSystem":""},{"effect":"Swelling","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Abscess of brain","Acute leukemia, disease","Anemia","Bacterial infectious disease","Bone marrow depression","Breastfeeding (mother)","Cerebral edema","Disease of liver","Disorder of lung","Epilepsy","Fibrosis of lung","Infectious disease","Kidney disease","Leukopenia","Liver function tests abnormal","Meningitis","Mycosis","Obstructive hydrocephalus","Pregnancy, function","Protozoal Infection","Pulmonary Infiltrates","Retinal hemorrhage","Significant Bleeding","Thrombocytopenic disorder","Viral disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Interstitial lung disease","drugRate":"","severity":"serious"},{"effect":"Renal failure","drugRate":"","severity":"serious"},{"effect":"Veno-occlusive disease","drugRate":"","severity":"serious"},{"effect":"Acute leukemia","drugRate":"","severity":"serious"},{"effect":"Bone marrow dysplasias","drugRate":"","severity":"serious"},{"effect":"Encephalopathy","drugRate":"","severity":"serious"},{"effect":"Seizures","drugRate":"","severity":"serious"},{"effect":"Skin necrosis","drugRate":"","severity":"serious"},{"effect":"Opportunistic infection","drugRate":"","severity":"serious"},{"effect":"Conjunctival hemorrhage","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["BCNU","Bis-Chlorethyl-Nitrosourea"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Carmustin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:16:39.088991+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T02:16:54.329284+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:16:46.001418+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Carmustin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:16:46.319938+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: RNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:16:47.494353+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL513/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:16:47.149122+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"0bdd91e1-fd94-4ce8-9c99-1b0fa6fe8ae4","title":"CARMUSTINE (CARMUSTINE ) KIT [ZYDUS PHARMACEUTICALS USA INC.]"},"aiSummary":"Carmustin, marketed by University Hospital Freiburg, is indicated for diffuse non-Hodgkin's lymphoma, large cell, with a key composition patent expiring in 2028. The drug's market position is bolstered by its established mechanism and indication, though specific revenue figures are not available. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.","ecosystem":[],"mechanism":{"target":"Glutathione reductase, mitochondrial"},"_scrapedAt":"2026-03-28T01:49:38.293Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:16:54.333640+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Diffuse non-Hodgkin's lymphoma, large cell","diseaseId":"diffuse-non-hodgkin's-lymphoma-large-cell","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Glioblastoma multiforme of brain","diseaseId":"glioblastoma-multiforme-of-brain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Glioma, malignant","diseaseId":"glioma-malignant","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hodgkin's disease","diseaseId":"hodgkin's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant neoplasm of brain","diseaseId":"malignant-neoplasm-of-brain","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Multiple myeloma","diseaseId":"multiple-myeloma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Non-Hodgkin's lymphoma","diseaseId":"non-hodgkin's-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT06915246","phase":"PHASE2","title":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","status":"RECRUITING","sponsor":"VIVUS LLC","startDate":"2025-03-12","conditions":"Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT05540340","phase":"PHASE1","title":"A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-09-09","conditions":"Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell","enrollment":39},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT05432635","phase":"PHASE1","title":"Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma","enrollment":15},{"nctId":"NCT01511562","phase":"PHASE2","title":"Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-09","conditions":"Lymphoma","enrollment":113},{"nctId":"NCT04150042","phase":"PHASE1","title":"SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells","status":"RECRUITING","sponsor":"General Oncology, Inc.","startDate":"2021-01-13","conditions":"Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation","enrollment":24},{"nctId":"NCT02896582","phase":"PHASE2","title":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-11-29","conditions":"Mantle Cell Lymphoma","enrollment":86},{"nctId":"NCT05083754","phase":"PHASE1","title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-08-31","conditions":"Glioblastoma Multiforme","enrollment":50},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT05521984","phase":"PHASE1","title":"Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-03","conditions":"Pediatric Brain Tumor, Pediatric Solid Tumor","enrollment":20},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT01840566","phase":"PHASE1","title":"High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":17},{"nctId":"NCT06626516","phase":"PHASE1, PHASE2","title":"Tebentafusp-tebn With LDT in Metastatic UM","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-15","conditions":"Metastatic Uveal Melanoma","enrollment":109},{"nctId":"NCT02570542","phase":"PHASE2","title":"Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-10","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":59},{"nctId":"NCT05052957","phase":"PHASE2","title":"hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2023-01-20","conditions":"Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma","enrollment":16},{"nctId":"NCT02684838","phase":"","title":"Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2016-04-26","conditions":"CNS Tumor","enrollment":272},{"nctId":"NCT03125642","phase":"PHASE2","title":"Auto Stem Cell Transplant for Lymphoma Patients","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04-20","conditions":"Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT06687772","phase":"PHASE2","title":"CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-01-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT01908777","phase":"PHASE2","title":"A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-07-16","conditions":"T Cell Non-Hodgkin Lymphoma","enrollment":47},{"nctId":"NCT07199296","phase":"PHASE2","title":"Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-07-01","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":45},{"nctId":"NCT04728633","phase":"PHASE2","title":"Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-09-27","conditions":"Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8","enrollment":28},{"nctId":"NCT02278796","phase":"PHASE2","title":"A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":108},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT03713580","phase":"PHASE1","title":"Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Non-hodgkin Lymphoma","enrollment":25},{"nctId":"NCT06377540","phase":"PHASE2","title":"MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-12-04","conditions":"Autologous Stem Cell Transplant, Classic Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT03583424","phase":"PHASE1, PHASE2","title":"Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":19},{"nctId":"NCT00641381","phase":"PHASE1","title":"Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2000-05-10","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT02797470","phase":"PHASE1, PHASE2","title":"Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIDS Malignancy Consortium","startDate":"2016-06-23","conditions":"HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma","enrollment":11},{"nctId":"NCT05427136","phase":"","title":"Early Pulmonary Dysfunction in Childhood Cancer Patients","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2021-06-01","conditions":"Pulmonary Dysfunction","enrollment":140},{"nctId":"NCT01476839","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-11-09","conditions":"Recurrent Adult Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT02342782","phase":"PHASE1","title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-06-08","conditions":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03382977","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","status":"RECRUITING","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-06","conditions":"Glioblastoma Multiforme","enrollment":98},{"nctId":"NCT04222062","phase":"PHASE2","title":"A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2020-11-06","conditions":"Brain Tumor - Metastatic","enrollment":100},{"nctId":"NCT04421378","phase":"PHASE1, PHASE2","title":"A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-06-08","conditions":"Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT06652139","phase":"PHASE2","title":"Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":82},{"nctId":"NCT06652165","phase":"PHASE2","title":"Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-01","conditions":"DLBCL","enrollment":66},{"nctId":"NCT03217643","phase":"PHASE2","title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","status":"COMPLETED","sponsor":"Imagine Institute","startDate":"2018-02-07","conditions":"Enteropathy Associated T-cell Lymphoma","enrollment":14},{"nctId":"NCT02085304","phase":"PHASE1, PHASE2","title":"Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM","status":"TERMINATED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2013-05-07","conditions":"Glioblastoma","enrollment":8},{"nctId":"NCT00968760","phase":"PHASE1","title":"CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-06-20","conditions":"Lymphoma, B-cell Lymphoma","enrollment":34},{"nctId":"NCT01827605","phase":"PHASE3","title":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-01","conditions":"Relapsed Follicular Lymphoma","enrollment":159},{"nctId":"NCT03072771","phase":"PHASE1","title":"Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":14},{"nctId":"NCT05029206","phase":"","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-05-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":174},{"nctId":"NCT01035463","phase":"PHASE1, PHASE2","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-11-12","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":74},{"nctId":"NCT00574509","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1996-03-04","conditions":"Lymphoma","enrollment":34},{"nctId":"NCT00080886","phase":"PHASE2","title":"Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2002-05-08","conditions":"Lymphoma","enrollment":68},{"nctId":"NCT00610883","phase":"PHASE2","title":"LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1990-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":17},{"nctId":"NCT00571493","phase":"PHASE1, PHASE2","title":"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-04-14","conditions":"Non-hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT00572013","phase":"PHASE1, PHASE2","title":"Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"1998-05-12","conditions":"Lymphoma","enrollment":32},{"nctId":"NCT00007852","phase":"PHASE2","title":"Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-09-01","conditions":"Lymphoma","enrollment":44},{"nctId":"NCT00006695","phase":"PHASE2","title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-04-01","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT05931263","phase":"PHASE3","title":"A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-01","conditions":"Newly Diagnosed Peripheral T-cell Lymphoma","enrollment":104},{"nctId":"NCT05922384","phase":"NA","title":"Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With Lymphoma","status":"RECRUITING","sponsor":"Affiliated Hospital of Guangdong Medical University","startDate":"2023-07-05","conditions":"HIV Infections, Lymphoma","enrollment":3},{"nctId":"NCT05863845","phase":"NA","title":"Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2023-06-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":52},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT03019640","phase":"PHASE2","title":"Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-10","conditions":"Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma","enrollment":22},{"nctId":"NCT05228249","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":""},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT01141712","phase":"PHASE2","title":"Autologous Transplant in HIV Patients (BMT CTN 0803)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2010-04","conditions":"Lymphoma, HIV","enrollment":43},{"nctId":"NCT03591861","phase":"NA","title":"Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2019-05-01","conditions":"Pediatric Brain Tumor","enrollment":2},{"nctId":"NCT05367856","phase":"PHASE2","title":"Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2022-05-28","conditions":"T Cell Lymphoma","enrollment":23},{"nctId":"NCT05518383","phase":"PHASE4","title":"B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-05-25","conditions":"Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma","enrollment":300},{"nctId":"NCT05466318","phase":"PHASE3","title":"ChiCGB vs BEAM in High-risk or R/R Lymphomas","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2022-07-01","conditions":"Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell","enrollment":306},{"nctId":"NCT03736616","phase":"PHASE2","title":"Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2019-08-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT03570983","phase":"PHASE2","title":"A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2018-09-05","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT05425654","phase":"PHASE2","title":"RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2021-05-17","conditions":"Primary CNS Lymphoma","enrollment":30},{"nctId":"NCT00712582","phase":"PHASE2","title":"Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-07-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT05398224","phase":"PHASE2","title":"R-MTX-zanbrutinib in Secondary CNS Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-02-26","conditions":"Secondary Central Nervous System Lymphoma","enrollment":45},{"nctId":"NCT00669669","phase":"PHASE1, PHASE2","title":"O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02-25","conditions":"Glioblastoma, Gliosarcoma","enrollment":12},{"nctId":"NCT03629873","phase":"PHASE2","title":"Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2018-02-01","conditions":"Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma","enrollment":69},{"nctId":"NCT05075681","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-11-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":50},{"nctId":"NCT05088226","phase":"PHASE2","title":"Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-12-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":50},{"nctId":"NCT00350181","phase":"PHASE2","title":"Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-08","conditions":"Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases","enrollment":11},{"nctId":"NCT00536601","phase":"NA","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2006-06-29","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","enrollment":174},{"nctId":"NCT02059239","phase":"PHASE1, PHASE2","title":"Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2014-06-04","conditions":"Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT04755023","phase":"PHASE2","title":"Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2005-12-21","conditions":"Oligodendroglioma; Oligoastrocytoma","enrollment":53},{"nctId":"NCT00591630","phase":"PHASE2","title":"Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-11-14","conditions":"Diffuse Large Cell Lymphoma, Lymphoma","enrollment":30},{"nctId":"NCT00004031","phase":"PHASE3","title":"SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1997-07","conditions":"Lymphoma","enrollment":397},{"nctId":"NCT02504359","phase":"PHASE1","title":"Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2015-07-20","conditions":"Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma","enrollment":11},{"nctId":"NCT02483000","phase":"PHASE1","title":"Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2017-02-01","conditions":"Burkitt Lymphoma, CD20-Positive Neoplastic Cells Present, Diffuse Large B-Cell Lymphoma","enrollment":3},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT00006386","phase":"PHASE2","title":"Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2001-03","conditions":"Brain and Central Nervous System Tumors","enrollment":80},{"nctId":"NCT04582604","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Decitabine for High Risk Hematological Malignancies","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":60},{"nctId":"NCT00536978","phase":"PHASE2","title":"Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-09","conditions":"Lymphoma, Leukemia","enrollment":22},{"nctId":"NCT01921387","phase":"PHASE1, PHASE2","title":"Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2013-10-09","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT00345865","phase":"PHASE2","title":"Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08-24","conditions":"Lymphoma","enrollment":473},{"nctId":"NCT00795665","phase":"PHASE2","title":"Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2008-06","conditions":"Glioma","enrollment":7},{"nctId":"NCT00632827","phase":"PHASE2","title":"Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2008-07-01","conditions":"Peripheral T-Cell Lymphoma","enrollment":21},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT00525590","phase":"PHASE2","title":"Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-12-12","conditions":"Metastatic Brain Cancer","enrollment":69},{"nctId":"NCT00005803","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1999-09","conditions":"Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma","enrollment":76},{"nctId":"NCT03579927","phase":"PHASE1, PHASE2","title":"CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-03","conditions":"CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT00342316","phase":"NA","title":"Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2003-12-18","conditions":"Acute Myeloid Leukemia","enrollment":340},{"nctId":"NCT02670109","phase":"PHASE2","title":"Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2018-02-01","conditions":"Triple-Negative Invasive Breast Carcinoma, Residual Tumor","enrollment":20},{"nctId":"NCT00984438","phase":"PHASE1, PHASE2","title":"Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme","status":"WITHDRAWN","sponsor":"University of Cincinnati","startDate":"2009-06","conditions":"Glioblastoma Multiforme","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL513"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":26,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Carmustin","genericName":"Carmustin","companyName":"University Hospital Freiburg","companyId":"university-hospital-freiburg","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T02:16:54.333640+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}